ATE272407T1 - Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff - Google Patents

Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff

Info

Publication number
ATE272407T1
ATE272407T1 AT95939926T AT95939926T ATE272407T1 AT E272407 T1 ATE272407 T1 AT E272407T1 AT 95939926 T AT95939926 T AT 95939926T AT 95939926 T AT95939926 T AT 95939926T AT E272407 T1 ATE272407 T1 AT E272407T1
Authority
AT
Austria
Prior art keywords
cancer immunotherapy
recombinant bacterial
specific cancer
bacterial vaccine
listeriolysin
Prior art date
Application number
AT95939926T
Other languages
English (en)
Inventor
Yvonne Paterson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23315786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE272407(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE272407T1 publication Critical patent/ATE272407T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT95939926T 1994-11-08 1995-11-03 Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff ATE272407T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/336,372 US6051237A (en) 1994-11-08 1994-11-08 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
PCT/US1995/014741 WO1996014087A1 (en) 1994-11-08 1995-11-03 Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector

Publications (1)

Publication Number Publication Date
ATE272407T1 true ATE272407T1 (de) 2004-08-15

Family

ID=23315786

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939926T ATE272407T1 (de) 1994-11-08 1995-11-03 Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff

Country Status (7)

Country Link
US (3) US6051237A (de)
EP (1) EP0790835B2 (de)
JP (2) JP3995712B2 (de)
AT (1) ATE272407T1 (de)
CA (1) CA2204666C (de)
DE (1) DE69533334T3 (de)
WO (1) WO1996014087A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264279A1 (en) * 1994-11-08 2007-11-15 Claudia Gravekamp Compositions and methods comprising a MAGE-b antigen
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
EP1012232B1 (de) * 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
DE19949595A1 (de) 1999-10-14 2001-05-03 Deutsches Krebsforsch CTAGE-Genfamilie
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US6892140B1 (en) * 2000-11-27 2005-05-10 Enteron, Inc. Immunogenic cancer peptides and uses thereof
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US20020193295A1 (en) * 2001-05-04 2002-12-19 Emanuel Calenoff Immunogenic peptides and uses thereof
DE10208653A1 (de) * 2002-02-28 2003-09-18 Medinnova Ges Med Innovationen Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren
AU2003219983A1 (en) * 2002-03-01 2003-09-16 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
US6688989B2 (en) * 2002-04-25 2004-02-10 Acushnet Company Iron club with captive third piece
CA2486980A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
US20090110702A1 (en) * 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004062597A2 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
CA2515298C (en) * 2003-02-06 2014-04-08 Cerus Corporation Modified free-living microbes, vaccine compositions and methods of use thereof
AU2004246999B2 (en) * 2003-02-06 2010-06-10 Aduro Biotech, Inc., Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US20050281783A1 (en) * 2003-10-15 2005-12-22 Kinch Michael S Listeria-based EphA2 vaccines
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
JP2008516614A (ja) * 2004-10-18 2008-05-22 メディミューン,インコーポレーテッド リステリア増殖のための高細胞密度法
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US7935804B2 (en) * 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
WO2007144647A2 (en) * 2006-06-15 2007-12-21 Timothy John Mitchell Adjuvant compositions
EP2056849A4 (de) * 2006-08-04 2010-09-08 Univ Pennsylvania Verfahren und zusammensetzungen zur behandlung von ige-vermittelten erkrankungen
ES2657168T3 (es) * 2006-08-15 2018-03-01 The Trustees Of The University Of Pennsylvania Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8277797B2 (en) 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
WO2010065613A2 (en) 2008-12-03 2010-06-10 The Johns Hopkins University Annexina2 as immunological target
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
EP2403935B1 (de) 2009-03-04 2017-05-10 The Trustees Of The University Of Pennsylvania Zusammensetzungen mit angiogenen faktoren und verwendungsverfahren dafür
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
EP2576791B8 (de) 2010-05-23 2016-12-21 Aduro BioTech, Inc. Verfahren und zusammensetzungen mit listeria zur hilfsbehandlung von krebs
JP5981436B2 (ja) 2010-10-01 2016-08-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 寄生的に感染している対象におけるワクチン不応答性を反転させるためのリステリアワクチンベクターの使用
US9200057B2 (en) 2010-11-17 2015-12-01 Providence Health & Services-Oregon Methods and compositions for inducing an immune response to EGFRvIII
US10702614B2 (en) 2011-02-15 2020-07-07 Albert Einstein College Of Medicine Radiobacteria for therapy of cancer
EP2683400A4 (de) 2011-03-11 2014-09-17 Advaxis Adjuvanzien auf listerien-basis
US10058599B2 (en) 2012-03-12 2018-08-28 Advaxis, Inc. Suppressor cell function inhibition following Listeria vaccine treatment
KR20150084033A (ko) 2012-11-06 2015-07-21 아두로 바이오테크, 인코포레이티드 조건적으로 약독화된 박테리아 종 그리고 이의 제조 방법 및 이의 용도
SG11201502792TA (en) 2012-12-27 2015-05-28 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
KR20160130774A (ko) 2014-02-18 2016-11-14 어드박시스, 인크. 바이오마커 지도된 다중-표적 면역치료
US10293039B2 (en) 2014-04-07 2019-05-21 The Board Of Trustees Of The University Of Illinois Attenuated Listeria monocytogenes mutant as a vaccine vector for the delivery of exogeneous antigens
EP3134510B1 (de) 2014-04-24 2023-11-01 Advaxis, Inc. Rekombinante listerienimpfstoffstämme und verfahren zur herstellung davon
US10925945B2 (en) 2014-10-13 2021-02-23 Providence Health & Services-Oregon Bacterial vaccines deficient in the 2-C-methyl-D-erythritol-4-phosphate pathway and methods of preparation and use thereof
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
JP2018512165A (ja) 2015-04-13 2018-05-17 アデュロ バイオテック,インコーポレイテッド 癌の治療のための免疫原性融合タンパク質
US10105427B2 (en) 2015-04-13 2018-10-23 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
IL273255B1 (en) 2017-09-19 2024-06-01 Advaxis Inc Preparations and methods for lyophilization of bacterial strains and listeria
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112538452A (zh) * 2020-11-26 2021-03-23 浙江农林大学 基于重组减毒单増李斯特菌的宫颈癌治疗性疫苗及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567041A (en) * 1977-12-08 1986-01-28 Likhite Vilas V Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4816253A (en) * 1977-12-08 1989-03-28 Likhite Vilas V Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
JPS63173594A (ja) * 1986-08-29 1988-07-18 Medeisa Shinyaku Kk 発癌遺伝子により誘導される分泌タンパク質
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
FR2686896B1 (fr) * 1992-01-31 1995-01-06 Pasteur Institut Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5876735A (en) * 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP0902086A1 (de) * 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberkolose Impfstoff
US6818002B2 (en) * 1999-02-02 2004-11-16 Samuel Shiber Vessel cleaner and barrier
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
JP2006502964A (ja) * 2002-02-06 2006-01-26 ジョンズ ホプキンス ユニバーシティ スクール オブ メディシン 特定の器官または組織に対する全身性免疫応答の標的化のための方法および組成物
JP2008516614A (ja) * 2004-10-18 2008-05-22 メディミューン,インコーポレーテッド リステリア増殖のための高細胞密度法

Also Published As

Publication number Publication date
US7135188B2 (en) 2006-11-14
DE69533334T2 (de) 2004-12-09
JPH10509448A (ja) 1998-09-14
EP0790835A4 (de) 2000-07-26
US6565852B1 (en) 2003-05-20
JP2007254485A (ja) 2007-10-04
WO1996014087A1 (en) 1996-05-17
EP0790835B1 (de) 2004-08-04
DE69533334D1 (de) 2004-09-09
DE69533334T3 (de) 2014-11-13
EP0790835A1 (de) 1997-08-27
US6051237A (en) 2000-04-18
CA2204666C (en) 2010-01-26
US20030202985A1 (en) 2003-10-30
JP3995712B2 (ja) 2007-10-24
CA2204666A1 (en) 1996-05-17
EP0790835B2 (de) 2010-06-23

Similar Documents

Publication Publication Date Title
ATE272407T1 (de) Spezifische krebs-immuntherapie mit rekombinantem bakteriellem impfstoff
FI924069A (fi) Terapeutiskt anvaendbara peptider och peptidfragment
EP1622648A4 (de) Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
HU9500571D0 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
DE60044665D1 (de) Her2/neu fusionsproteine
MX9703017A (es) Inmunizacion oral con plantas transgenicas.
DE60040651D1 (de) Methoden zur behandlung von tumoren und metastasen unter verwendung einer anti-angiogenen und immun-therapien
GR3030716T3 (en) Selective system scan for multizone radiotelephone subscriber units.
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
DE3853454D1 (de) Therapeutische Zusammensetzungen gegen Streptokokken-Infektionen, transformierte Wirte, Verfahren zur Immunisierung und gentechnologisch hergestellte Produkte.
MXPA01003240A (es) Mamaglobina, una proteina secretada del cancer mamario especifica de mama.
CA2254082A1 (en) Metastatic colorectal cancer vaccine
AU4803785A (en) Cross-reactive and protective epitopes of circumsporozoite proteins
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
WO2002000250A3 (en) Hiv-1 vaccines and screening methods therefor
ES8801127A1 (es) Un procedimiento para preparar una vacuna auto antigena en forma de virus modificado de la viruela vacuna.
GB9401795D0 (en) Vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties